Clinical Trial

Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To explore the application of Sacituzumab Tirumotecan in neoadjuvant treatment of early-stage TNBC, a multicenter, Phase II clinical study of Sacituzumab Tirumotecan in neoadjuvant treatment of early-stage TNBC is proposed. The study aims to evaluate the efficacy and safety of Sacituzumab Tirumotecan and to provide a new treatment option for neoadjuvant treatment of early-stage TNBC.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-04.
Trial Details
NCT Number NCT07007780
Lead Sponsor Xijing Hospital
Conditions Triple -Negative Breast Cancer
Enrollment 35 participants
Start Date 2025-08-20
Primary Completion 2026-08-31 (estimated)
Study Completion 2027-08-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-29